The epigenetic modifier MLL4 has an unassuming name—the 4, for instance, indicates it’s just one in a family of such modifiers. But MLL4 is quite special: In a specific type of leukemia, it drives disease progression, while in solid tumors, it acts as a suppressor.
The paradoxical nature of MLL4 made it a compelling enigma for Rockefeller University’s Robert Roeder, a pioneer in the field of genetic transcription. Now his Laboratory of Biochemistry and Molecular Biology at Rockefeller University has used a combination of biochemistry, genetics and structural biology to find surprising new characteristics of MLL4 that expand our understanding of its range of functions, including its relationship to a tumor-suppressing protein. The findings, published in Molecular Cell, could illuminate how the MLL4 complex helps switch genes on—including cancer genes in leukemia.
“This research demonstrates that MLL4 has functions in transcription that were entirely unknown before,” says Roeder. “And because MLL4 is a key regulator of gene activity, it’s important to understand how it works—especially in cancer cells.”









